Australian-developed coeliac disease vaccine fast-tracked by the FDA

By VIVA! Communications | January 16, 2019

A vaccine for coeliac disease could soon be made available with the Australian-developed immunisation gaining fast-track designation from America’s Food and Drug Administration. ImmusanT’s Nexvax2, developed at the Walter and Eliza Hall Institute (WEHI) in Victoria, is set for a prompt review at the completion of its trial phases. Currently phase two, involving 150 patients…

Read More